NYSE:NVO

Novo Nordisk A/S Stock Forecast, Price & News

$112.12

+3.69 (+3.40%)

(As of 06/24/2022 12:00 AM ET)

Add

Compare

Today's Range: $110.58
▼
$112.20
50-Day Range: $103.24
▼
$116.37
52-Week Range: $82.11
▼
$122.16

Volume: 1.43 million shs
Average Volume: 1.52 million shs
Market Capitalization: $264.02 billion

P/E Ratio: 33.37
Dividend Yield: 1.36%
Price Target: $655.40

30 days | 90 days | 365 days | Advanced Chart

Receive NVO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novo Nordisk A/S and its competitors with MarketBeat's FREE daily newsletter.

NVO Stock Forecast (MarketRank)

Overall MarketRank^™

2.53 out of 5 stars

4.3 Analyst's Opinion

Consensus Rating
Novo Nordisk A/S has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on 11 buy ratings, 6 hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $655.40, Novo Nordisk A/S has a forecasted upside of 484.6% from its current price of $112.12.
Amount of Analyst Coverage
Novo Nordisk A/S has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

4.0 Community Rank

Outperform Votes
Novo Nordisk A/S has received 374 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Novo Nordisk A/S has received 254 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Novo Nordisk A/S has received 59.55% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Novo Nordisk A/S and other stocks. Vote “Outperform” if you believe NVO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NVO will underperform the S&P 500 over the long term. You may vote once every thirty days.

2.5 Dividend Strength

Dividend Yield
Novo Nordisk A/S pays a meaningful dividend of 1.36%, higher than the bottom 25% of all stocks that pay dividends.
Dividend Growth
Novo Nordisk A/S does not have a long track record of dividend growth.
Dividend Coverage
The dividend payout ratio of Novo Nordisk A/S is 44.05%. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Novo Nordisk A/S will have a dividend payout ratio of 35.32% next year. This indicates that Novo Nordisk A/S will be able to sustain or increase its dividend.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Novo Nordisk A/S insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 0.07% of the stock of Novo Nordisk A/S is held by insiders.

1.9 Earnings and Valuation

Earnings Growth
Earnings for Novo Nordisk A/S are expected to grow by 20.40% in the coming year, from $3.48 to $4.19 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Novo Nordisk A/S is 33.37, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 13.65.
Price to Earnings Ratio vs. Sector
The P/E ratio of Novo Nordisk A/S is 33.37, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 11.94.
Price to Earnings Growth Ratio
Novo Nordisk A/S has a PEG Ratio of 2.13. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Novo Nordisk A/S has a P/B Ratio of 23.46. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Novo Nordisk A/S (NYSE:NVO)

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

June 23, 2022 | seekingalpha.com

Novo Nordisk, Echosens team up to advance early diagnosis, awareness for liver disease

June 23, 2022 | finance.yahoo.com

Camp Huronda welcomes back campers for a long-awaited reopening and unveils the new Insul-Inn

June 22, 2022 | finance.yahoo.com

Echosens and Novo Nordisk Announce Partnership to Increase Awareness and Advance Early Diagnosis of NASH

June 16, 2022 | seekingalpha.com

BlackRock lowers stake in Novo Nordisk

June 15, 2022 | finance.yahoo.com

Is Novo Nordisk (NVO) a Smart Long-Term Investment?

June 14, 2022 | finance.yahoo.com

Novo Nordisk A/S: Our New Capsule System Tackles Biopharma ESG Risk Tied to U.S. Drug Pricing and Cost-Effectiveness

June 8, 2022 | americanbankingnews.com

Novo Nordisk A/S (NYSE:NVO) Upgraded to Overweight at JPMorgan Chase & Co.

June 6, 2022 | seekingalpha.com

Novo Nordisk A/S (NVO) Presents at ADA 82nd Scientific Sessions (Transcript)

June 3, 2022 | nasdaq.com

Novo Nordisk: Main Phases Of ONWARDS 1, ONWARDS 6 Phase 3a Trials Achieve Primary Objectives

June 3, 2022 | finance.yahoo.com

Novo Nordisk achieves primary objectives of ONWARDS 1 and 6 trials with once-weekly insulin icodec demonstrating superior reduction in HbA1c vs insulin glargine U100 in ONWARDS 1

June 1, 2022 | americanbankingnews.com

Novo Nordisk A/S (NYSE:NVO) Upgraded to Buy by Guggenheim

May 31, 2022 | seekingalpha.com

Novo Nordisk upgraded to buy at Guggenheim ahead of upcoming cardiac data for Wegovy

May 27, 2022 | finance.yahoo.com

Should You Be Adding Novo Nordisk (NYSE:NVO) To Your Watchlist Today?

See More Headlines

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NYSE:NVO
CUSIP: N/A
CIK: 353278
Web: www.novonordisk.com
Phone: (454) 444-8888
Fax: 45-4449-0555
Employees: 45,000
Year Founded: 1923

Company Calendar

Ex-Dividend for 4/5 Dividend: 3/25/2022
Dividend Payable: 4/05/2022
Last Earnings: 4/29/2022
Today: 6/24/2022
Next Earnings (Estimated): 8/03/2022
Fiscal Year End: 12/31/2022

Price Target and Rating

Average Stock Price Forecast: $655.40
High Stock Price Forecast: $900.00
Low Stock Price Forecast: $130.00
Forecasted Upside/Downside: +484.6%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.55555555555556
Research Coverage: 18 Analysts

Profitability

EPS (Most Recent Fiscal Year): $3.36
Trailing P/E Ratio: 33.37
Forward P/E Ratio: 32.22
P/E Growth: 2.13
Net Income: $7.60 billion
Net Margins: 33.16%
Pretax Margin: 40.97%
Return on Equity: 72.67%
Return on Assets: 27.05%

Debt

Debt-to-Equity Ratio: 0.36
Current Ratio: 0.91
Quick Ratio: 0.69

Sales & Book Value

Annual Sales: $22.40 billion
Price / Sales: 11.79
Cash Flow: $3.79 per share
Price / Cash Flow: 29.55
Book Value: $4.78 per share
Price / Book: 23.46

Miscellaneous

Outstanding Shares: 2,354,800,000
Free Float: N/A
Market Cap: $264.02 billion
Optionable: Optionable
Beta: 0.47

Social Links

Novo Nordisk A/S Frequently Asked Questions

Should I buy or sell Novo Nordisk A/S stock right now?: 18 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Novo Nordisk A/S in the last twelve months. There are currently 1 sell rating, 6 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" Novo Nordisk A/S stock.
View analyst ratings for Novo Nordisk A/S or view top-rated stocks.
What is Novo Nordisk A/S's stock price forecast for 2022?: 18 brokerages have issued 12-month target prices for Novo Nordisk A/S's shares. Their NVO stock forecasts range from $130.00 to $900.00. On average, they anticipate Novo Nordisk A/S's share price to reach $655.40 in the next twelve months. This suggests a possible upside of 484.6% from the stock's current price.
View analysts' price targets for Novo Nordisk A/S or view top-rated stocks among Wall Street analysts.
How has Novo Nordisk A/S's stock price performed in 2022?: Novo Nordisk A/S's stock was trading at $112.00 at the beginning of 2022. Since then, NVO stock has increased by 0.1% and is now trading at $112.12.
View the best growth stocks for 2022 here.
Are investors shorting Novo Nordisk A/S?: Novo Nordisk A/S saw a decrease in short interest in the month of May. As of May 31st, there was short interest totaling 1,710,000 shares, a decrease of 29.0% from the May 15th total of 2,410,000 shares. Based on an average daily trading volume, of 1,470,000 shares, the short-interest ratio is presently 1.2 days. Approximately 0.1% of the company's shares are short sold.
View Novo Nordisk A/S's Short Interest.
When is Novo Nordisk A/S's next earnings date?: Novo Nordisk A/S is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022.
View our earnings forecast for Novo Nordisk A/S.
How were Novo Nordisk A/S's earnings last quarter?: Novo Nordisk A/S (NYSE:NVO) released its quarterly earnings results on Friday, April, 29th. The company reported $0.94 EPS for the quarter, beating analysts' consensus estimates of $0.85 by $0.09. The company earned $6.34 billion during the quarter, compared to analysts' expectations of $5.82 billion. Novo Nordisk A/S had a trailing twelve-month return on equity of 72.67% and a net margin of 33.16%.
View Novo Nordisk A/S's earnings history.
How often does Novo Nordisk A/S pay dividends? What is the dividend yield for Novo Nordisk A/S?: Novo Nordisk A/S declared a Semi-Annual dividend on Wednesday, March 2nd. Stockholders of record on Monday, March 28th will be paid a dividend of $0.741 per share on Tuesday, April 5th. This represents a dividend yield of 1.1%. The ex-dividend date is Friday, March 25th. This is a positive change from Novo Nordisk A/S's previous Semi-Annual dividend of $0.56.
View Novo Nordisk A/S's dividend history.
Is Novo Nordisk A/S a good dividend stock?: Novo Nordisk A/S(NYSE:NVO) pays an annual dividend of $1.48 per share and currently has a dividend yield of 1.36%. The dividend payout ratio of Novo Nordisk A/S is 44.05%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Novo Nordisk A/S will have a dividend payout ratio of 35.32% next year. This indicates that Novo Nordisk A/S will be able to sustain or increase its dividend.
View Novo Nordisk A/S's dividend history.
Who are Novo Nordisk A/S's key executives?: Novo Nordisk A/S's management team includes the following people:
Mr. Lars Fruergaard Jorgensen, Pres, CEO & Member of Management Board (Age 56, Pay $5.11M)
Mr. Karsten Munk Knudsen, Exec. VP, CFO & Member of the Management Board (Age 51, Pay $1.89M)
Mr. Henrik Ehlers Wulff, Exec. VP, Head of Product Supply, Quality & IT and Member of the Management Board (Age 52, Pay $1.99M)
Ms. Camilla Sylvest, Exec. VP, Head of Commercial Strategy & Corp. Affairs and Member of the Management Board (Age 50, Pay $1.89M)
Ms. Monique Carter, Exec. VP, Head of People & Organisation and Member of Management Board (Age 49, Pay $1.43M)
Mr. Maziar Mike Doustdar, Exec. VP, Head of International Operations & Member of the Management Board (Age 52)
Mr. Douglas J. Langa, Exec. VP, Head of North America Operations & Member of Management Board (Age 56)
Mr. Ludovic Helfgott, Exec. VP, Head of Rare Disease & Member of Management Board (Age 48)
Dr. Martin Holst Lange, Exec. VP, Head of Devel. & Member of the Management Board (Age 52)
Dr. Marcus Schindler Ph.D., EVP, Head of Research & Early Devel., Chief Scientific Officer & Member of the Management Board (Age 56)
What is Lars Fruergaard Jørgensen's approval rating as Novo Nordisk A/S's CEO?: 372 employees have rated Novo Nordisk A/S CEO Lars Fruergaard Jørgensen on Glassdoor.com. Lars Fruergaard Jørgensen has an approval rating of 92% among Novo Nordisk A/S's employees. This puts Lars Fruergaard Jørgensen in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Novo Nordisk A/S's key competitors?: Some companies that are related to Novo Nordisk A/S include Johnson & Johnson (JNJ), Eli Lilly and (LLY), Pfizer (PFE), Roche (RHHBY), AbbVie (ABBV), Merck & Co., Inc. (MRK), AstraZeneca (AZN), Abbott Laboratories (ABT), Novartis (NVS), Bristol-Myers Squibb (BMY), Sanofi (SNY), GSK (GSK), CSL (CSLLY), Zoetis (ZTS) and Vertex Pharmaceuticals (VRTX).
View all of NVO's competitors.
What other stocks do shareholders of Novo Nordisk A/S own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Novo Nordisk A/S investors own include Gilead Sciences (GILD), AbbVie (ABBV), Pfizer (PFE), NVIDIA (NVDA), Johnson & Johnson (JNJ), Alibaba Group (BABA), QUALCOMM (QCOM), Cisco Systems (CSCO), AT&T (T) and Abbott Laboratories (ABT).
What is Novo Nordisk A/S's stock symbol?: Novo Nordisk A/S trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVO."
Who are Novo Nordisk A/S's major shareholders?: Novo Nordisk A/S's stock is owned by many different retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (0.78%), Fisher Asset Management LLC (0.00%), Bank of America Corp DE (0.00%), Loomis Sayles & Co. L P (0.00%), Jennison Associates LLC (0.23%) and Capital International Investors (0.00%).
View institutional ownership trends for Novo Nordisk A/S.
Which major investors are selling Novo Nordisk A/S stock?: NVO stock was sold by a variety of institutional investors in the last quarter, including Folketrygdfondet, Clearbridge Investments LLC, Renaissance Technologies LLC, Capital International Investors, Loomis Sayles & Co. L P, State Street Corp, UBS Group AG, and Grimes & Company Inc..
View insider buying and selling activity for Novo Nordisk A/S or view top insider-selling stocks.
Which major investors are buying Novo Nordisk A/S stock?: NVO stock was purchased by a variety of institutional investors in the last quarter, including Jennison Associates LLC, BlackRock Inc., Lord Abbett & CO. LLC, Twin Tree Management LP, Vantage Investment Partners LLC, Northern Trust Corp, Alyeska Investment Group L.P., and JPMorgan Chase & Co..
View insider buying and selling activity for Novo Nordisk A/S or or view top insider-buying stocks.
How do I buy shares of Novo Nordisk A/S?: Shares of NVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Novo Nordisk A/S's stock price today?: One share of NVO stock can currently be purchased for approximately $112.12.
How much money does Novo Nordisk A/S make?: Novo Nordisk A/S (NYSE:NVO) has a market capitalization of $264.02 billion and generates $22.40 billion in revenue each year. The company earns $7.60 billion in net income (profit) each year or $3.36 on an earnings per share basis.
How many employees does Novo Nordisk A/S have?: Novo Nordisk A/S employs 45,000 workers across the globe.
Does Novo Nordisk A/S have any subsidiaries?: The following companies are subsidiares of Novo Nordisk A/S: Aldaph SpA, Beijing Novo Nordisk Pharmaceuticals Science & Technology Co. Ltd., CS Solar Fund XIV LLC, Calibrium, Corvidia, Corvidia Therapeutics Inc., Dicerna Pharmaceuticals, Dicerna Pharmaceuticals Inc., Emisphere Technologies, Emisphere Technologies Inc., MB2 LLC, NNE A/S, Neotope Neuroscience Limited, Novo Nordisk, Novo Nordisk (China) Pharmaceuticals Co. Ltd., Novo Nordisk (Pty) Limited, Novo Nordisk (Shanghai) Pharma Trading Co. Ltd., Novo Nordisk B.V., Novo Nordisk Canada Inc., Novo Nordisk Colombia SAS, Novo Nordisk Comércio Produtos Farmacêuticos Lda., Novo Nordisk Denmark A/S, Novo Nordisk Egypt LLC, Novo Nordisk Farma OY, Novo Nordisk Farma S.R.L., Novo Nordisk Farma dooel, Novo Nordisk Farmacéutica Limitada, Novo Nordisk Farmacêutica do Brasil Ltda., Novo Nordisk Finance (Netherlands) B.V., Novo Nordisk Health Care AG, Novo Nordisk Hellas Epe., Novo Nordisk Holding Limited, Novo Nordisk Hong Kong Limited, Novo Nordisk Hrvatska d.o.o., Novo Nordisk Hungária Kft., Novo Nordisk Inc., Novo Nordisk India Holding Pte Ltd., Novo Nordisk India Private Limited, Novo Nordisk Kazakhstan LLP, Novo Nordisk Kenya Ltd., Novo Nordisk Lanka (PVT) Ltd, Novo Nordisk Limited, Novo Nordisk Limited Liability Company, Novo Nordisk Ltd, Novo Nordisk Mexico S.A. de C.V., Novo Nordisk North America Operations A/S, Novo Nordisk Norway AS, Novo Nordisk Panama S.A., Novo Nordisk Pars, Novo Nordisk Peru S.A.C., Novo Nordisk Pharma (Malaysia) Sdn Bhd, Novo Nordisk Pharma (Private) Limited, Novo Nordisk Pharma (Singapore) Pte Ltd., Novo Nordisk Pharma (Taiwan) Ltd., Novo Nordisk Pharma (Thailand) Ltd., Novo Nordisk Pharma AG, Novo Nordisk Pharma Argentina S.A., Novo Nordisk Pharma EAD, Novo Nordisk Pharma GmbH, Novo Nordisk Pharma Gulf FZE, Novo Nordisk Pharma Inc., Novo Nordisk Pharma Korea Ltd., Novo Nordisk Pharma Limited, Novo Nordisk Pharma Ltd., Novo Nordisk Pharma Operations (Business Area) Sdn Bhd, Novo Nordisk Pharma Operations A/S, Novo Nordisk Pharma S.A., Novo Nordisk Pharma SARL, Novo Nordisk Pharma SAS, Novo Nordisk Pharma Sp.z.o.o., Novo Nordisk Pharma d.o.o., Novo Nordisk Pharma d.o.o. Belgrade (Serbia), Novo Nordisk Pharmaceutical Industries LP, Novo Nordisk Pharmaceutical Services Sp. z o.o., Novo Nordisk Pharmaceuticals (Philippines) Inc., Novo Nordisk Pharmaceuticals A/S, Novo Nordisk Pharmaceuticals Ltd., Novo Nordisk Pharmaceuticals Pty. Ltd., Novo Nordisk Pharmatech A/S, Novo Nordisk Pharmatech US Inc., Novo Nordisk Production SAS, Novo Nordisk Production Support LLC, Novo Nordisk Produção Farmacêutica do Brasil Ltda., Novo Nordisk Region AAMEO and LATAM A/S, Novo Nordisk Region China A/S, Novo Nordisk Region Europe A/S, Novo Nordisk Region Japan & Korea A/S, Novo Nordisk Research Center Indianapolis Inc., Novo Nordisk Research Center Seattle Inc., Novo Nordisk S.P.A., Novo Nordisk Saglik Ürünleri Tic. Ltd. Sti., Novo Nordisk Saudi for Trading, Novo Nordisk Scandinavia AB, Novo Nordisk Service Centre (India) Pvt. Ltd., Novo Nordisk Slovakia s.r.o., Novo Nordisk Tunisie SARL, Novo Nordisk US Bio Production Inc., Novo Nordisk US Commercial Holdings Inc., Novo Nordisk US Holdings Inc., Novo Nordisk Ukraine LLC, Novo Nordisk Venezuela Casa de Representación C.A., Novo Nordisk d.o.o., Novo Nordisk s.r.o., PT. Novo Nordisk Indonesia, S.A. Novo Nordisk Pharma N.V., UAB Novo Nordisk Pharma, Xellia Pharmaceuticals, Ziylo, and Ziylo Limited.
Read More
When was Novo Nordisk A/S founded?: Novo Nordisk A/S was founded in 1923.
How can I contact Novo Nordisk A/S?: Novo Nordisk A/S's mailing address is Novo Alle, Bagsvaerd G7, 2880. The official website for Novo Nordisk A/S is www.novonordisk.com. The company can be reached via phone at (454) 444-8888, via email at [email protected], or via fax at 45-4449-0555.

This page (NYSE:NVO) was last updated on 6/24/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Novo Nordisk A/S Stock Forecast, Price & News

Receive NVO Stock News and Ratings via Email

NVO Stock Forecast (MarketRank)

Overall MarketRank™

4.3 Analyst's Opinion

4.0 Community Rank

Outperform Votes

Underperform Votes

Community Sentiment

2.5 Dividend Strength

0.0 Company Ownership

1.9 Earnings and Valuation

About Novo Nordisk A/S (NYSE:NVO)

NVO Stock News Headlines

Industry, Sector and Symbol

Company Calendar

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Novo Nordisk A/S Frequently Asked Questions

Should I buy or sell Novo Nordisk A/S stock right now?

What is Novo Nordisk A/S's stock price forecast for 2022?

How has Novo Nordisk A/S's stock price performed in 2022?

Are investors shorting Novo Nordisk A/S?

When is Novo Nordisk A/S's next earnings date?

How were Novo Nordisk A/S's earnings last quarter?

How often does Novo Nordisk A/S pay dividends? What is the dividend yield for Novo Nordisk A/S?

Is Novo Nordisk A/S a good dividend stock?

Who are Novo Nordisk A/S's key executives?

What is Lars Fruergaard Jørgensen's approval rating as Novo Nordisk A/S's CEO?

Who are some of Novo Nordisk A/S's key competitors?

What other stocks do shareholders of Novo Nordisk A/S own?

What is Novo Nordisk A/S's stock symbol?

Who are Novo Nordisk A/S's major shareholders?

Which major investors are selling Novo Nordisk A/S stock?

Which major investors are buying Novo Nordisk A/S stock?

How do I buy shares of Novo Nordisk A/S?

What is Novo Nordisk A/S's stock price today?

How much money does Novo Nordisk A/S make?

How many employees does Novo Nordisk A/S have?

Does Novo Nordisk A/S have any subsidiaries?

When was Novo Nordisk A/S founded?

How can I contact Novo Nordisk A/S?

MarketBeat Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources

Overall MarketRank^™